(Total Views: 226)
Posted On: 03/23/2020 4:45:28 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.5 Million in Private Placement
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced its March 19, 2020, closing on its previously announced private offering of common stock and warrants resulting in gross proceeds of $3,498,612 to the Company. Per the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance, as well as Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. Predictive Oncology intends to use the net proceeds for general corporate purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced its March 19, 2020, closing on its previously announced private offering of common stock and warrants resulting in gross proceeds of $3,498,612 to the Company. Per the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance, as well as Series B warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. Predictive Oncology intends to use the net proceeds for general corporate purposes.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
